| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| T1015 |
Clinic visit/encounter, all-inclusive |
15,734 |
13,893 |
$1.77M |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
1,994 |
1,886 |
$230K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
1,681 |
1,518 |
$180K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
1,141 |
1,091 |
$133K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
3,550 |
3,000 |
$125K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
549 |
512 |
$53K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
1,984 |
1,740 |
$37K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
441 |
394 |
$7K |
| 99381 |
|
59 |
55 |
$5K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
242 |
204 |
$5K |
| 90648 |
|
472 |
419 |
$5K |
| 87428 |
|
88 |
83 |
$4K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
984 |
798 |
$4K |
| 90633 |
|
583 |
543 |
$3K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
212 |
178 |
$3K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
79 |
58 |
$3K |
| 90670 |
|
1,182 |
1,056 |
$2K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
2,579 |
1,976 |
$2K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
559 |
477 |
$2K |
| 90686 |
|
653 |
580 |
$2K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
74 |
63 |
$762.19 |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
2,212 |
900 |
$665.23 |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
2,541 |
1,113 |
$541.36 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
1,774 |
1,593 |
$540.61 |
| 87420 |
|
178 |
151 |
$450.80 |
| 90734 |
|
72 |
60 |
$395.04 |
| 90710 |
|
124 |
101 |
$268.00 |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
30 |
28 |
$184.50 |
| 90696 |
|
39 |
31 |
$136.32 |
| 99309 |
Subsequent nursing facility care, per day, low to moderate complexity |
137 |
78 |
$69.00 |
| 87276 |
|
80 |
64 |
$40.50 |
| 87275 |
|
80 |
64 |
$33.57 |
| 90461 |
|
749 |
610 |
$12.35 |
| 90677 |
|
223 |
220 |
$0.03 |
| 96160 |
|
26 |
24 |
$0.01 |
| 90723 |
|
470 |
415 |
$0.01 |
| 90680 |
|
785 |
707 |
$0.01 |
| 90647 |
|
191 |
168 |
$0.01 |
| 99310 |
Prolong nursin fac eval 15m |
105 |
96 |
$0.00 |
| 90715 |
|
30 |
24 |
$0.00 |
| 90700 |
|
58 |
54 |
$0.00 |
| 90649 |
|
12 |
12 |
$0.00 |
| 99308 |
Subsequent nursing facility care, per day, straightforward |
14 |
12 |
$0.00 |
| 90698 |
|
139 |
125 |
$0.00 |
| 90697 |
|
213 |
210 |
$0.00 |